What is claimed is:

1. A compound selected from the group consisting of

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

methyl (1*S*,3*R*,5*S*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate;

methyl (1*R*,3*R*,5*R*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate;

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1*R*,3*R*,5*R*)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1*R*,3*R*,5*R*)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile; and

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1*R*,3*R*,5*R*)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 that is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile.

3. The compound of claim 1 that is a pharmaceutically acceptable salt of 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile.

4. The compound of claim 1 that is methyl (1*S*,3*R*,5*S*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-

(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate.

5. The compound of claim 1 that is a pharmaceutically acceptable salt of methyl (1*S*,3*R*,5*S*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate.

6. The compound of claim 1 that is methyl (1*R*,3*R*,5*R*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate.

7. The compound of claim 1 that is a pharmaceutically acceptable salt of methyl (1*R*,3*R*,5*R*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate.

8. The compound of claim 1 that is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1*R*,3*R*,5*R*)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile.

9. The compound of claim 1 that is a pharmaceutically acceptable salt of 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1*R*,3*R*,5*R*)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile.

10. The compound of claim 1 that is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1*R*,3*R*,5*R*)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile.

11. The compound of claim 1 that is a pharmaceutically acceptable salt of 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1*R*,3*R*,5*R*)-2-(1-

fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile.

12. The compound of claim 1 that is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1*R*,3*R*,5*R*)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile.

13. The compound of claim 1 that is a pharmaceutically acceptable salt of 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1*R*,3*R*,5*R*)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile.

14. A pharmaceutical composition comprising the compound of any one of claims 1-13, and at least one pharmaceutically acceptable carrier or excipient.

15. Use of a compound of any one of claims 1-13, or a pharmaceutical composition of claim 14, in the manufacture of a medicament for treating a disease or disorder associated with activity of KRAS.

16. Use of a compound of any one of claims 1-13, or a pharmaceutical composition of claim 14, in the manufacture of a medicament for treating a disease or disorder associated with activity of a KRAS protein harboring a G12D mutation.

17. Use according to claim 16, wherein the disease or disorder is an immunological or inflammatory disorder.

18. Use according to claim 17, wherein the immunological or inflammatory disorder is Ras-associated lymphoproliferative disorder or juvenile myelomonocytic leukemia caused by a somatic mutation of KRAS.

19. Use of a compound of any one of claims 1-13, or a pharmaceutical composition of claim 14, in the manufacture of a medicament for treating a cancer.

20. Use according to claim 19, wherein the cancer is selected from a carcinoma, a hematological cancer, a sarcoma, and glioblastoma.

21. Use according to claim 20, wherein the cancer is a hematological cancer selected from a myeloproliferative neoplasm, a myelodysplastic syndrome, chronic and juvenile myelomonocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, and multiple myeloma.

22. Use according to claim 20, wherein the cancer is a carcinoma is selected from pancreatic, colorectal, lung, bladder, gastric, esophageal, breast, head and neck, cervical, skin, and thyroid carcinomas.

23. Use according to any one of claims 19-22, wherein the cancer is a cancer is characterized by a KRAS protein harboring a G12D mutation.

24. Use according to claim 19, wherein the cancer is pancreatic cancer.

25. Use according to claim 24, wherein the cancer is pancreatic ductal adenocarcinoma.

26. Use according to claim 19, wherein the cancer is colorectal cancer

27. Use according to claim 26, wherein the cancer is colorectal carcinoma.

28. Use according to claim 19, wherein the cancer is lung cancer.

29. Use according to claim 28, wherein the cancer is non small cell lung cancer.